Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 3
2010 5
2011 1
2012 3
2013 4
2014 7
2015 23
2016 25
2017 27
2018 49
2019 53
2020 59
2021 59
2022 59
2023 81
2024 80
2025 89
2026 82

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

633 results

Results by year

Filters applied: . Clear all
Page 1
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. Bidard FC, et al. J Clin Oncol. 2022 Oct 1;40(28):3246-3256. doi: 10.1200/JCO.22.00338. Epub 2022 May 18. J Clin Oncol. 2022. PMID: 35584336 Free PMC article. Clinical Trial.
METHODS: This randomized, open-label, phase III trial enrolled patients with ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretreatment with a cyclin-dependent kinase 4/6 inhibitor, and 1 chemot …
METHODS: This randomized, open-label, phase III trial enrolled patients with ER-positive/HER2-negative advanced breast cancer …
Overcoming Endocrine Resistance in Breast Cancer.
Hanker AB, Sudhan DR, Arteaga CL. Hanker AB, et al. Cancer Cell. 2020 Apr 13;37(4):496-513. doi: 10.1016/j.ccell.2020.03.009. Cancer Cell. 2020. PMID: 32289273 Free PMC article. Review.
Estrogen receptor-positive (ER(+)) breast cancer is the most common breast cancer subtype. Treatment of ER(+) breast cancer comprises interventions that suppress estrogen production and/or target the ER directly (overall labeled as end …
Estrogen receptor-positive (ER(+)) breast cancer is the most common breast cancer subtype. Treatment of ER(+) …
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
Bardia A, Cortés J, Bidard FC, Neven P, Garcia-Sáenz J, Aftimos P, O'Shaughnessy J, Lu J, Tonini G, Scartoni S, Paoli A, Binaschi M, Wasserman T, Kaklamani V. Bardia A, et al. Clin Cancer Res. 2024 Oct 1;30(19):4299-4309. doi: 10.1158/1078-0432.CCR-24-1073. Clin Cancer Res. 2024. PMID: 39087959 Free PMC article. Clinical Trial.
PURPOSE: Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor-positive (ER+), HER2- metastatic breast cancer and tumors harbor …
PURPOSE: Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocri …
Recent advances in targeted strategies for triple-negative breast cancer.
Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, Wu K. Zhu S, et al. J Hematol Oncol. 2023 Aug 28;16(1):100. doi: 10.1186/s13045-023-01497-3. J Hematol Oncol. 2023. PMID: 37641116 Free PMC article. Review.
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). ...Moreover, immune checkpoint inhibitors, for e …
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estroge …
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Brett JO, Spring LM, Bardia A, Wander SA. Brett JO, et al. Breast Cancer Res. 2021 Aug 15;23(1):85. doi: 10.1186/s13058-021-01462-3. Breast Cancer Res. 2021. PMID: 34392831 Free PMC article. Review.
In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase inhibition. ...These therapies include estrogen receptor-targeting agents, such as se …
In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common cause of acquired resistance to the …
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, Zamagni C, Cui J, Cazzaniga M, Cil T, Jerzak KJ, Fuentes C, Yoshinami T, Rodriguez-Lescure A, Sezer A, Fontana A, Guarneri V, Molckovsky A, Mouret-Reynier MA, Demirci U, Zhang Y, Valota O, Lu DR, Martignoni M, Parameswaran J, Zhi X, Hamilton EP; VERITAC-2 Study Group. Campone M, et al. N Engl J Med. 2025 Aug 7;393(6):556-568. doi: 10.1056/NEJMoa2505725. Epub 2025 May 31. N Engl J Med. 2025. PMID: 40454645 Clinical Trial.
METHODS: In this phase 3, open-label, randomized trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer who had received one previous line of cyclin-dependent kinase 4 and 6 inhibitor therapy plu …
METHODS: In this phase 3, open-label, randomized trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER …
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.
Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, Iwata H, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, McClain S, Bidard FC. Turner N, et al. Future Oncol. 2023 Mar;19(8):559-573. doi: 10.2217/fon-2022-1196. Epub 2023 Apr 18. Future Oncol. 2023. PMID: 37070653 Free article.
ESR1 mutation (ESR1m) is a frequent cause of acquired resistance to aromatase inhibitor (AI) plus cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), which is a first-line therapy for hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2 …
ESR1 mutation (ESR1m) is a frequent cause of acquired resistance to aromatase inhibitor (AI) plus cyclin-dependent kinase 4 and 6 inh …
Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches.
Raheem F, Karikalan SA, Batalini F, El Masry A, Mina L. Raheem F, et al. Int J Mol Sci. 2023 Nov 11;24(22):16198. doi: 10.3390/ijms242216198. Int J Mol Sci. 2023. PMID: 38003387 Free PMC article. Review.
Endocrine therapy is the main treatment for hormone receptor-positive (HR+) breast cancer. ...In this article, we review the mechanisms of acquired endocrine resistance in HR+ advanced breast cancer and discuss current and future investig …
Endocrine therapy is the main treatment for hormone receptor-positive (HR+) breast cancer. ...In this article, w …
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
Bhave MA, Quintanilha JCF, Tukachinsky H, Li G, Scott T, Ross JS, Pasquina L, Huang RSP, McArthur H, Levy MA, Graf RP, Kalinsky K. Bhave MA, et al. Breast Cancer Res Treat. 2024 Oct;207(3):599-609. doi: 10.1007/s10549-024-07376-w. Epub 2024 Jun 14. Breast Cancer Res Treat. 2024. PMID: 38872062 Free PMC article.
BACKGROUND: The treatment landscape for HR(+)HER2(-) metastatic breast cancer (MBC) is evolving for patients with ESR1 mutations (mut) and PI3K/AKT pathway genomic alterations (GA). We sought to inform clinical utility for comprehensive genomic profiling (CGP …
BACKGROUND: The treatment landscape for HR(+)HER2(-) metastatic breast cancer (MBC) is evolving for patients with ESR1 …
ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. Jeselsohn R, et al. Nat Rev Clin Oncol. 2015 Oct;12(10):573-83. doi: 10.1038/nrclinonc.2015.117. Epub 2015 Jun 30. Nat Rev Clin Oncol. 2015. PMID: 26122181 Free PMC article. Review.
These mutations are clustered in a 'hotspot' within the ligand-binding domain (LBD) of the ER and lead to ligand-independent ER activity that promotes tumour growth, partial resistance to endocrine therapy, and potentially enhanced metastatic capacity; thus, ER LBD …
These mutations are clustered in a 'hotspot' within the ligand-binding domain (LBD) of the ER and lead to ligand-independent ER activity tha …
633 results